InVivium Capital

The firm targets early-stage through growth-equity investments, covering seed, expansion, and late-stage rounds according to public record. InVivium's platform spans three offices — Stamford, Chicago, and New York — which positions it to source deals across both the Northeast's healthcare corridor and the Midwest's life-sciences ecosystem. The firm has not disclosed specific sector concentration limits, portfolio companies, or a formal asset-class allocation strategy.

InVivium Capital has not publicly disclosed its principals, investment committee members, or senior leadership team. The firm's filings and website do not name a founder, managing partner, or CIO in any readily available public source. This absence of named operators is atypical for an early-stage private equity platform and suggests the firm has maintained a deliberately low-profile posture since inception.

The firm has not disclosed its funding sources, limited partner composition, or committed capital base. For firms operating across multiple offices with a seed-to-growth mandate, typical LP profiles include family offices, endowments, fund-of-funds, and high-net-worth individuals — but InVivium's specific capital stack cannot be confirmed from the public record.

The firm does not publish details on its origination or sourcing model. Its three-office structure — Stamford, Chicago, and New York — implies a multi-hub network that could provide regional deal flow advantages in the Northeast and Midwest. Without disclosed portfolio companies or named investment partners, the actual sourcing channels remain opaque.

InVivium has not disclosed whether it operates through a traditional commingled fund structure, special purpose vehicles, or a deal-by-deal syndication model. The firm's private equity designation and early-to-growth-stage mandate are compatible with any of these structures, but the specific vehicle architecture is not part of the public record.